Warner-lambert Company

Reata Pharmaceuticals, Inc.

Abbvie Inc.

William Howard Roark

Bruce D Roth

Xin Jiang

Melean Visnick

Bradley W Caprathe

Gary Louis Bolton

Chitase Lee

Eric Anderson

Joseph Armand Picard

David T Connor

Roderick J Sorenson

David Christopher Horwell

Bharat Kalidas Trivedi

Drago R Sliskovic

Ila Sircar

Joseph Thomas Repine

James S Kaltenbronn

Jurgen Kleinschroth

Edward Roberts

Ann Holmes

Karen Elaine Sexton

James P Hudspeth

Janak Khimchand Padia

James Lester Hicks

Rolf Wagner

Annette M Doherty

James Bernard Kramer

Allan C Krueger

Diane H Boschelli

Patrick Michael O'Brien

Helen Tsenwhei Lee

Pamela L Donner

David Charles Rees

Francis John Tinney

David J Grampovnik

Christopher F Bender

Hui-Ju J Chen

Howard Robin Heyman

Reginald S Richardson

Jason P Shanley

Michael Andrew Stier

Amy Mae Bunker

Mark W Creswell

Michael J Rozema

Alexander W Chucholowski

Richard Dennis Dyer

William Glen Harter

Martha R Hotema

Sonya Shah Khatana

Ly Pham

Bradley William Caprathe

Jason Shanley

Howard Heyman

Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.

Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Disclosed herein are C4 modified oleanolic acid derivatives of the formula: Formula (X) or Formula (XII), as well as analogs thereof, wherein the variables are defined herein. In addition, disclosed herein are pharmaceutical compositions of these derivatives or analogs, methods for their manufacture, and methods for their use, including for the prevention and treatment of diseases or disorders associated with overproduction of IL-17. 

C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses

The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein R, R, R, R, R, R, m, n, X and Y are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.

Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof,wherein R, Q, R, R, and Rare as defined in the specification. The invention also provides related pharmaceutical compositions, methods of use, and combinations.

Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors

The present invention provides compounds of Formula (I) wherein Q, Q, Q, Q, Y, Y, and Z are as defined in the description, and pharmaceutically acceptable salts thereof, and C-Calkyl esters thereof, which are useful for the treatment of diseases responsive to the inhibition of the enzyme 15-lipoxygenase. Thus, the compounds of Formula (I) and their pharmaceuticalyl acceptable salts are useful for treating diseases with an inflammatory component, including atherosclerosis, diseases involving chemotaxis of monocytes, inflammation, stroke, coronary artery disease, asthma, arthritis, colorectal cancer, and psoriasis.

6,5-Fused bicyclic heterocycles

This invention provides indole and benzimidazole 15-lipoxygenase (15-LO) inhibitors of the formula where one of Yand Yis CH, N, or NH, and the other is Rincludes H, halo, HN, COOH, alkyl; Rincludes halo, alkyl, and alkoxy; Z is C, CH, or NR; Ris H or oxycabonyl; and each X is independently H, alkyl, alkoxy, or halo.

Indole and benzimidazole 15-lipoxygenase inhibitors

Phenylene alkyne matrix metalloproteinase inhibitors

Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis

N-acyl sulfamic acid esters useful as hypocholesterolemic agents

The present invention is directed to compounds useful for the regulation of cholesterol of Formula I, methods for using them and pharmaceutical compositions thereof, ##STR1## wherein Ar and Ar.sup.1 are each independently selected from unsubstituted or substituted phenyl which substituents are from 1-5 in number and are each independently selected from alkyl, alkoxy, hydroxy, halogen, nitro, trifluoromethyl, COOH, and COOalkyl;

Phosphonamide ACAT inhibitors

Growing community of inventors

Ann Arbor, MI, United States of America

William Howard Roark